Answers are grounded in this paper and cite their sources.
Background Sleeve lobectomy (SL) preserves lung parenchyma in selected patients with centrally located non-small cell lung cancer (NSCLC). We updated the comparative evidence on SL versus pneumonectomy (PN), focusing on long-term survival and perioperative outcomes. Methods PubMed, Embase, and the Cochrane Library were searched to June 10, 2025, for studies comparing SL with PN. Individual observations were reconstructed from published Kaplan–Meier curves with study identifiers retained. Study-specific hazard ratios (HRs) were pooled using restricted maximum likelihood (REML) with modified Hartung–Knapp confidence intervals, and a study-stratified Cox model was fitted as a complementary analysis. Perioperative outcomes were pooled with the same random-effects approach. Results Twenty-seven studies were included, of which 25 contributed to the meta-analysis. SL was associated with better overall survival (OS; 19 studies, 5,491 patients; HR 0.62, 95% CI 0.55–0.70) and disease-free survival (DFS; seven studies, 3,675 patients; HR 0.70, 95% CI 0.61–0.81), and with lower 30-day (OR 0.54, 95% CI 0.31–0.92) and 90-day mortality (OR 0.36, 95% CI 0.17–0.77). Bronchopleural fistula, reoperation, and hospital stay did not differ significantly. The OS association persisted among matched cohorts (HR 0.62, 95% CI 0.52–0.75), whereas pooled source-reported multivariable estimates were less precise (HR 0.70, 95% CI 0.48–1.03). Conclusions In observational cohorts, SL was associated with better long-term survival and lower early mortality than PN. Residual confounding by indication precludes causal inference, but the findings support parenchyma-preserving sleeve resection when an R0 resection is technically and oncologically feasible.
No takes yet. Share an insight, caveat, or question.
Oliveira et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: